Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients

Jennifer Bré(University of St Andrews), David J. Harrison(NHS Lothian), Paul A. Reynolds(University of St Andrews), In Hwa Um(University of St Andrews), Sarah P. Blagden(Churchill Hospital), Awa Sarr(University of St Andrews), Peter Mullen(University of Southern California)

Cancer Research

July 1, 2018

10.1158/1538-7445.am2018-1855

Cited by 2

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

High-frequency developmental abnormalities in p53-deficient mice

|Current Biology|1995|467

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201